- This event has passed.
Webinar: Managing Stage III NSCLC Patients with the PACIFIC Regimen
June 10 @ 5:00 pm - 6:00 pm EDT
About this Webinar: Panelists in Medical Oncology and Radiation Oncology will discuss the management of patients with stage III non-small cell lung cancer. Specifically, discussion will focus on patients receiving chemoradiation followed by durvalamab, in accordance with the PACIFIC Trial. Panelists hope to touch on issues of patient selection, radiation treatment planning considerations, optimizing patient tolerance of chemotherapy, and managing toxicities of chemoradiation. Submit questions for the panelists here.
This webinar is put on with the support of AstraZeneca.
Speakers: Drs. Eric Nadler, Alex Whitley, Steven Finkelstein, Ryan Whitaker, and Brian Persing
Registration is required. Click here to register.
About the speakers:
Dr. Eric Nadler
Eric Nadler, M.D., M.P.P. received a BA with highest honors from Wesleyan University double majoring in molecular biology and philosophy. He received his joint M.D/M.P.P. from Harvard Medical School and Master in Public Policy from Harvard University’s Kennedy School of Government. He completed his internship and residency at Brigham and Women’s Hospital in Boston, MA and his oncology fellowship at Dana Farber Cancer Institute/MGH in Boston, MA. Dr. Nadler serves as a Medical Director of US Oncology Health Informatics and Internet Technology. He remains active in USON research committees in lung cancer, head and neck cancer, and sarcoma within the developmental committees.
Dr. Alex Whitley
Alex Whitley, M.D. grew up on a small farm just north of Charlotte, North Carolina and attended Catawba College. He received his B.S. in biology as a collegiate soccer player. From there he attended the Medical University of South Carolina, MUSC, in Charleston South Carolina starting a dual degree program with an MD and PhD. He completed his PhD at MUSC before transferring to the University of Alabama at Birmingham, UAB, and completing his MD. He completed an intern year in surgery before transitioning into his radiation oncology residency at UAB. He was the first American Board of Radiology, ABR, Holman Research Scholar at UAB during his residency working with Dr. Eddy Yang on targeting DNA repair pathways improving the therapeutic ratio in various cancers. After residency, he accepted a position at Central Alabama Radiation Oncology, CARO, and is now a partner/owner. He has expanded his practice with a new location as well pending affiliation status with NRG Oncology. Nationally he is a peer reviewer for the American College of Radiation Oncology, ACRO, and he is a member of the Practice Guideline Implementation Network committee for the American Society of Clinical Oncology, ASCO. Additionally, he has been awarded ACRO fellowship. He has extensively published in areas from cell signaling to DNA repair and more recently national guidelines. While not working, he enjoys spending time with his family including his wife, Heather, a professor in the College of Pharmacy at Auburn University, and 3 children, Reese, Colin, and Lane.
Dr. Steven Finkelstein
Steven Finkelstein, M.D., DABR, FACRO received his M.D. from the University of Michigan in 1997. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) as Clinical Associate in 1999 and completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship in 2004. Following completion of an additional radiation oncology residency, Dr. Finkelstein was selected as Chief Resident in Radiation Oncology at Moffitt Cancer Center/University of South Florida. In 2019, Dr. Finkelstein joined the US Oncology Network at Florida Cancer Affiliates. Dr. Finkelstein has a special interest in the study and patient care and research of a variety of cancers, using radiation driven, and personalized systemic therapy. He has given national and international lectures, published numerous professional journal articles and book chapters. He also serves on the editorial board of key international journals, including the ASCO Associated Editor for Immunotherapy. For these contributions, Dr. Finkelstein was elected to the ACRO Board of Chancellors and Chair of Education in 2018.
Dr. Ryan Whitaker
Ryan Whitaker, M.D., Ph.D. received his BSE in Chemical Engineering from the University of Iowa in 2008. He went on to attend the Medical University of South Carolina in Charleston where he completed a dual degree (MD/PhD) program with his graduate work focusing on mitochondrial-targeted drug development. He completed his intern year at Scripps Mercy Hospital in San Diego before beginning his radiation oncology residency at Vanderbilt University where he currently serves as Chief Resident. Dr. Whitaker has a special interest in the study of radiotherapy/ immunotherapy combinations with a particular focus in thoracic oncology. He currently serves as the first AstraZeneca-ASTRO Research Fellow in AZ US Medical Affairs contributing to AstraZeneca’s immune-oncology program.
Dr. Brian Persing
Brian Persing, M.D. received his and undergraduate degree in chemistry and his medical degree from the University of South Dakota. He then completed his Internal Medicine residency and Hematology and Oncology Fellowship at the University of Mississippi Medical Center. He entered into practice on the Mississippi Gulf Coast and remained there for 11 years. With a passion still fueled for teaching, he then took an academic position at the University of South Alabama Health (USA) at the Mitchell Cancer Institute as an Assistant Professor of Interdisciplinary Clinical Oncology ultimately being named as the Program Director for the Oncology Fellowship Program. Currently, he is the President of Mississippi Oncology Society and is the Mississippi representative to the American Society of Clinical Oncology (ASCO) State Affiliate Council where he serves on the Executive Subcommittee. He remains an advocate for patients in Mississippi as well as Alabama now, actively speaking with legislators on state and national levels and is part of the ASCO Advocacy Summitt. His passion for the care of patients dealing with lung cancer is leading to and establishing a comprehensive and multidisciplinary lung cancer program at USA Health.
Dr. Brandi Page
Brandi Page, M.D. is an Assistant Professor of Radiation Oncology and Molecular Radiation Sciences and the Associate Residency Program Director at Johns Hopkins. Her primary clinical practice locations are at the Johns Hopkins – Suburban Hospital in Bethesda, MD, and the Johns Hopkins Proton Center at the Sibley Memorial Hospital in DC, where she is the Proton Fellowship Director. Since her time at Johns Hopkins Dr. Page has specialized in treatment of brain tumors and head and neck cancers. She has contributed to publications, articles, posters and lectures. Dr. Page’s research interests include mitigation of long-term toxicity and improving long-term survivorship challenges in patients receiving radiotherapy for brain tumors and head and neck cancers.